产品活性： PF-07104091 hydrate 是一种高效选择性的 CDK2/cyclin E1 和 GSK3β 抑制剂，其 Ki 分别为 1.16 和 537.81 nM。PF-07104091 hydrate ...

γ-herpesvirus genomes encode an abundance of homologues of cellular factors, including cyclin and Bcl-2. These viral homologues differ from their cellular counterparts in that the viral proteins ...

Cyclin-dependent kinases (CDKs) are protein kinases involved in critical cellular processes, such as cell cycle or transcription, whose activity requires association with specific cyclin subunits.

Poster presentation details are below: Author: Molina et al Title: CID-078, a first-in-class oral cyclin A/B-RxL inhibitor, elicits anti-tumor activity in breast cancer patient-derived xenograft ...

Zentalis Pharmaceuticals has won a U.S. Food and Drug Administration fast-track designation for its lead product candidate azenosertib for certain cancer patients with high levels of the Cyclin E1 ...

In a large-animal model study, researchers have found that heart attack recovery is aided by the injection of heart muscle ...

In a large-animal model study, researchers have found that heart attack recovery is aided by injection of heart muscle cell spheroids derived from human induced pluripotent stem cells, or hiPSCs, that ...

In tumoral cells, the modulation of the G1/S phases of cell cycle is destabilized by amplification and high expression of cyclin E (CCNE) or by mutation or loss of retinoblastoma 1 (RB1) gene. Cancer ...

Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) made a significant announcement regarding its entry into an Agreement and Plan ...

RVU-120 is under clinical development by Ryvu Therapeutics and currently in Phase II for Anemia. According to GlobalData, Phase II drugs for Anemia have a 53% phase transition success rate (PTSR) ...

All rights reserved. Registered office: The Institute of Cancer Research, 123 Old Brompton Road, London, SW7 3RP. A Charity, Not for Profit. Company Limited by Guarantee. Registered in England No.